HOME >> BIOLOGY >> NEWS
Other highlights in the August 4 JNCI

ut its association with response to taxane-based chemotherapy is not clear. Dennis J. Slamon, M.D., Ph.D., of the University of California, Los Angeles, and colleagues analyzed retrospective data from a randomized clinical trial that had treated patients with metastatic breast cancer with either taxane-based epirubicinpaclitaxel (ET) chemotherapy or epirubicincyclophosphamide (EC) chemotherapy.

They found that HER-2/neu overexpression does not adversely influence response to first-line ET or EC chemotherapy and that a taxane-containing regimen, such as ET, may provide a preferential benefit to patients with tumors that overexpress HER-2/neu.

Contact: Kim Irwin, Women's Cancer Program Area, Jonsson Cancer Center, 310-206-2805, kirwin@mednet.ucla.edu

Researchers Examine Targeted Therapy for Neuroblastoma in Mouse Model

Survival is poor in patients with advanced-stage neuroblastoma, a cancer of nerve cells in infants and children, and there is a need to develop better treatments. Mirco Ponzoni, Ph.D., of G. Gaslini Children's Hospital in Genoa, Italy, and colleagues show that by encapsulating an antisense oligonucleotide targeting an oncogene and activating the innate immune system in a liposome that specifically targets neuroblastoma cells, neuroblastoma-bearing mice lived longer than mice given any other treatment in the study.

Contact: Mirco Ponzoni, G. Gaslini Children's Hospital, 39-010-563-6342, mircoponzoni@ospedale-gaslini.ge.it

Also in the August 4 JNCI:

  • No Survival Benefit for Adjuvant Chemotherapy for Colon Cancer after 10 Years:
    http://www.eurekalert.org/emb_releases/2004-08/jotn-acf072904.php
  • Activated Signaling Pathway May Predict Lung Cancer Patients' Response to Gefitinib:


  • Contact: Sarah L. Zielinski
    jncimedia@oupjournals.org
    301-841-1287
    Journal of the National Cancer Institute
    3-Aug-2004


    Page: 1 2 3

    Related biology news :

    1. Other highlights in the September 1 JNCI
    2. Other highlights in the August 18 JNCI
    3. Other highlights in the July 7 JNCI
    4. Other highlights in the June 16 JNCI
    5. Other Highlights in the June 2 JNCI
    6. Other highlights in the May 19 JNCI
    7. Other highlights in the May 5 JNCI
    8. Other highlights of the March 17 issue of JNCI
    9. Other highlights in the March 3 issue of JNCI
    10. Other highlights in the February 18 issue of JNCI
    11. Other highlights in the February 4 issue of JNCI

    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    TAG: Other highlights the August JNCI

    (Date:2/18/2015)... SUNNYVALE, Calif. , Feb. 18, 2015  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Conference, Boston, MA Tuesday, March 3, ... Institutional Investors Conference, Orlando, FL Wednesday, ... Accessing Live Webcasts To access the live webcasts for these ...
    (Date:2/12/2015)... Conn. , Feb. 12, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62/113114 for DISTRIBUTED ... DEVICES. The patent further establishes NXT-ID,s position ... its intellectual property portfolio the ability for multiple devices ...
    (Date:2/9/2015)... -- Lintec of America recently announced an exclusive license to ... including sheets, yarns and ribbons, developed at the University ... vast industrial resources of the global Lintec Group, headquartered ... America is forming the Nano-Science and Technology Center (NSTC) ... scaling up the manufacturing and commercialization of nano engineered ...
    Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
    (Date:3/3/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ) has ... 2015 - 2025" report to their offering. ... an extensive study on the marketed and pipeline gene ... in this field for over a decade but there ... markets; one approved in the EU). There are many ...
    (Date:3/3/2015)... Adaptive Biotechnologies announced today that Chad ... of Director as Chair of the Audit Committee. ... oversees all finance, treasury and accounting functions. Since joining ... treasury and accounting functions, and led the finance organization ... he was named Puget Sound Business Journal,s CFO of ...
    (Date:3/3/2015)...  Regenicin, Inc. (OTC Bulletin Board: RGIN ... and commercialization of regenerative cell therapies to restore the ... it has received the final payment to conclude The ... Bulletin Board: AMBS ). ... payments due to Regenicin in the amount of $2.3 ...
    (Date:3/3/2015)... BOSTON, MA (PRWEB) March 03, 2015 ... Print Supply Chain, today announced the expansion of its ... quality, color-matched print to 850 the world’s largest cities ... Supply Chain extends to 137 countries providing global enterprises ... the print procurement process from online order to real-world ...
    Breaking Biology Technology:Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 4
    Cached News: